NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance With Nasdaq Continued Listing Rules
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance With Nasdaq Continued Listing Rules
ZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the closing of a private placement offering consisting of the issuance and sale of 806,452 common shares, par value CHF 0.80 per share and common share purchase warrants to purchase 806,452 common shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.2 million. The warrants have a term of five years and have an exercise price of $4.25 per share.
苏黎世,瑞士/ ACCESSWIRE / 2024年10月15日 / NLS制药有限公司(纳斯达克: NLSP)(纳斯达克: NLSPW)("NLS"或"公司")是一家瑞士临床阶段生物制药公司,专注于为患有罕见和复杂中枢神经系统疾病的患者发现和开发创新疗法,今天宣布闭市推出由发行和出售806,452股普通股、每股面值CHF 0.80瑞士法郎和购买806,452股普通股的普通股认购权组成的定向增发,总购买价格为3.97美元,募集总收益为320万美元。认购权期限为五年,行权价格为每股4.25美元。
In addition, the Company closed a debt purchase agreement, with an accredited investor, pursuant to which in exchange for the satisfaction of the Company's debt in the aggregate amount of $4.0 million held by the investor, the Company agreed to issue 806,452 newly designated convertible preferred shares, at a purchase price of approximately $4.96. The preferred shares contain a conversion price of $4.96 per share. Pursuant to the debt purchase agreement, the Company agreed to grant the investor the right to purchase up to an additional $10.0 million worth of convertible preferred shares beginning six months after the closing and continuing for as long as the investor owns preferred shares.
此外,公司与一家合格投资者签订了债务购买协议,根据该协议,公司将发行约400万美元的债务,以换取投资者持有的总额为400万美元的债务,公司同意以约4.96美元的价格发行806,452股新指定的可转换优先股。优先股包含每股4.96美元的转换价格。根据债务购买协议,公司同意授予投资者购买额高达1000万美元的可转换优先股的权利,购买权从闭市后六个月起生效,持续至投资者持有优先股。
NLS also announced that it believes it has regained compliance with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), due to the fact that its common shares have traded above $1.00 for ten consecutive trading days. In addition, due in part to the foregoing transactions, NLS announced that it believes that it satisfies the stockholders' equity requirement of at least $2.5 million pursuant to Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market.
NLS还宣布认为已恢复符合纳斯达克上市规则5550(a)(2)的最低买盘价要求,因为其普通股已在连续十个交易日以上1.00美元交易。此外,部分原因归功于前述交易,NLS宣布认为自身符合至少250万美元股东权益要求,符合纳斯达克资本市场继续上市的5550(b)(1)规则。
The securities described above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
上述证券是根据《1933年证券法》第4(a)(2)节的登记要求中修改("证券法")第506(b)规则下的豁免责任提供和出售的。这些证券未根据证券法或适用州证券法注册。因此,除符合证券法的有效注册声明或适用的豁免登记要求及该州的证券法外,这些证券不得在美国以外的地方提供或出售。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
本新闻稿不构成销售或发售此类证券的报价,也不会在任何未经任何此类状态或管辖区的证券法规注册或取得资格的情况下销售这些证券。
About NLS Pharmaceutics Ltd.
关于NLS Pharmaceutics Ltd.
NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS是一家全球发展阶段的生物制药公司,与一流合作伙伴和国际知名科学家合作,专注于为罕见和复杂中枢神经系统疾病患者的创新疗法的发现和开发,这些患者有待医疗需求。总部设在瑞士,成立于2015年,NLS由一支经验丰富的管理团队领导,具有开发和推广产品候选药物的记录。欲了解更多信息,请访问。
Safe Harbor Statement
Safe Harbor声明
This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws, including statements related to the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. For example, the Company is using forward-looking statements when discussing the potential conversion of preferred shares or exercise of warrants and that it believes it is in compliance with applicable Nasdaq rules. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.
本新闻稿包含根据美国联邦证券法明示或暗示的前瞻性陈述,包括与发行时间和完成、与发行相关的惯例收盘条件的满足以及资金用途有关的陈述。例如,公司在讨论优先股转换或认股权行使潜力时使用前瞻性陈述,并表示公司相信自身符合适用的纳斯达克规定。这些前瞻性陈述及其影响是仅基于纳思达交易所管理层目前的期望,并受多种可能导致实际结果与前瞻性陈述描述不符的因素和不确定性的影响。除非法律另有规定,纳思达交易所对公开发布对这些前瞻性陈述的任何修订不承担义务,以反映本日期后的事件或情况或反映出乎意料的事件的发生。有关影响纳思达交易所的风险和不确定性的更详细信息载于NLS截至2023年12月31日年度报告第20-F表的“风险因素”标题下,该报告已向美国证券交易委员会或SEC提交,可在SEC网站www.sec.gov上获得,并载于纳思达交易所随后向SEC提交的申报文件中。
For additional information:
有关详细信息:
Elena Thyen, CFO
NLS Pharmaceutics Ltd.
+41(0) 44 512 21 50
etp@nls-pharma.com
Elena Thyen,首席财务官
NLS制药有限公司
+41(0) 44 512 21 50
etp@nls-pharma.com
SOURCE: NLS Pharmaceutics Ltd.
来源:NLS Pharmaceutics Ltd.